FMC Corporation Reports $3.47 Billion Revenue and $2.24 Billion Net Loss for 2025

**FMC Corporation Reports 2025 Financial Results, Announces Strategic Review**

FMC Corporation (FMC), a global agricultural sciences company, reported revenue of $3.47 billion for the year ended December 31, 2025, a decrease of 18% compared to $4.25 billion in 2024. This decline was primarily attributed to one-time commercial actions taken to prepare the company's India commercial business for sale, resulting in revenue charges of approximately $422 million. Excluding these actions, revenue decreased by 8%, driven by a 6% price decline and a 1% volume increase. The company reported a net loss attributable to FMC stockholders of $2.24 billion, compared to net income of $341.1 million in the prior year. This significant decrease was primarily due to a $1.36 billion goodwill write-off and $522 million in charges related to the India commercial business divestiture.

The company's gross margin for 2025 was $1.28 billion, a 22% decrease from $1.65 billion in 2024. Gross margin as a percentage of revenue was 37%. Excluding the impact of the India commercial business actions, gross margin as a percentage of revenue was 41%, an increase from 39% in the prior year due to cost improvements. Selling, general, and administrative expenses increased by 6% to $684.9 million, while research and development expenses decreased by 4% to $266.1 million. The company's adjusted after-tax earnings from continuing operations attributable to FMC stockholders, a non-GAAP measure, was $372 million, a 15% decrease from $436.3 million in 2024.

Operationally, FMC is focused on executing its 2026 priorities, including strengthening its balance sheet through debt reduction, improving the competitiveness of its core portfolio, managing the post-patent transition for Rynaxypyr® active, and supporting the growth of new active ingredients. The company's strategy includes divesting its India commercial business, with the sale expected to conclude in 2026, and actively participating in the India market through a supply agreement. FMC is also implementing Project Foundation, a multi-year program to optimize its manufacturing footprint and reduce structural costs, which generated $165 million in cost benefits in 2024. The company employs approximately 5,500 people globally, with a focus on safety, inclusion, and sustainability.

In February 2026, FMC's Board of Directors authorized the exploration of strategic options, including a potential sale of the company, to unlock shareholder value and ensure the long-term success of its growth and core portfolios. The company believes that additional investment in its four new active ingredients and broader development pipeline could enhance shareholder value. The strategic review is at a preliminary stage, and there is no assurance that the process will result in any transaction. FMC's common stock outstanding as of December 31, 2025, was 124,934,056 shares.

Looking ahead, FMC anticipates continued pressure on pricing due to competitive market dynamics and lower Rynaxypyr® active pricing. The company expects to reduce costs for the full year, despite expected pressure in the first quarter due to the timing of tariffs and manufacturing variances. FMC remains committed to leading the industry in safety, inclusion, and sustainability, with a focus on delivering products that improve agricultural productivity while protecting the environment for future generations.